Ibrutinib in Chronic Lymphocytic Leukemia
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 25 July 2025 | Viewed by 3398
Special Issue Editor
Interests: chronic lymphocytic leukemia; tumor microenvironment; targeted therapy; immunomodulation
Special Issue Information
Dear Colleagues,
Introduction of Bruton Tyrosine kinase (BTK) inhibitors in the clinical practice has deeply altered the treatment paradigm of Chronic Lymphocytic Leukemia (CLL) patients. In particular, ibrutinib is the first BTK inhibitor used in the treatment of CLL that is able to bind covalently to cysteine residue (C481) in the ATP-binding domain of the BTK kinase leading to inhibition of its enzymatic activity. Inhibition of BTK prevents downstream activation of the BCR pathway affecting cell growth, proliferation, homing and survival of the leukemic B cells.
CLL is the most common adult leukemia in Western countries and is an example of hematological disease where cooperation between genetic defects and tumor microenvironmental interaction is involved in pathogenesis. In this scenario, CLL is a disease considered as “addicted to the host”; indeed, the crosstalk between leukemic cells and the tumor microenvironment is essential for leukemic clone maintenance supporting CLL cells’ survival, proliferation, and protection from drug-induced apoptosis.
Although ibrutinib has shown excellent effects on CLL cell component inducing mobilization of lymphocytes from tissue into the blood with the consequent cell death, recently different studies have demonstrated the on-target effects on off-tumor cells related to tumor microenvironment.
This Special Issue aims to summarize the current knowledge and cutting-edge research on BTK inhibitors in CLL.
In this Special Issue, original research articles and reviews are welcome.
Dr. Stefania Fiorcari
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- BTK inhibitors
- ibrutinib
- chronic lymphocytic leukemia
- targeted therapy
- BTK
- tumor microenvironment
- drug combination
- immunomodulation
- drug resisitance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
